These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1450667)

  • 21. Fotemustine and DTIC combination in patients with disseminated malignant melanoma.
    Merimsky O; Inbar M; Chaitchik S
    Am J Clin Oncol; 1992 Feb; 15(1):84-6. PubMed ID: 1550085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
    Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME
    Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
    Mohr P; Makki A; Breitbart E; Schadendorf D
    Melanoma Res; 1998 Apr; 8(2):166-9. PubMed ID: 9610871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
    Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
    Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical treatment and other combination regimens.
    Bajetta E; Del Vecchio M; Bajetta R; Canova S
    Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
    [No Abstract]   [Full Text] [Related]  

  • 29. Systemic treatments for advanced cutaneous melanoma.
    Anderson CM; Buzaid AC; Legha SS
    Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
    Margolin KA; Di Giacomo AM; Maio M
    Semin Oncol; 2010 Oct; 37(5):468-72. PubMed ID: 21074062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
    Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
    Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
    Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
    Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
    Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
    [No Abstract]   [Full Text] [Related]  

  • 35. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
    Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
    Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
    Lee SM; Margison GP; Woodcock AA; Thatcher N
    Br J Cancer; 1993 Jun; 67(6):1356-60. PubMed ID: 8512821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
    Binder M; Winkler A; Dorffner R; Glebowski E; Wolff K; Pehamberger H
    Eur J Cancer; 1992; 28A(11):1814-6. PubMed ID: 1389516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
    Seeber A; Binder M; Steiner A; Wolff K; Pehamberger H
    Eur J Cancer; 1998 Dec; 34(13):2129-31. PubMed ID: 10070323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
    Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Nguyen BB; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre J; de Gislain C; Bensadoun JR; Clavel M
    Cancer Radiother; 2003 Feb; 7(1):1-8. PubMed ID: 12648711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
    Jacquillat C; Khayat D; Banzet P; Weil M; Fumoleau P; Avril MF; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
    Cancer; 1990 Nov; 66(9):1873-8. PubMed ID: 2224783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.